ASCO 2024 - Global Speaker Series - Exciting update on the overall survival data from the DESTINY-Breast03 trial

Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.